Regional action of brofaromine on rat brain MAO-A and MAO-B

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 7, 1998, Pages 1141-1155

  Gerardy, Jean ^a,b   Dresse, Albert ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Institute of Pathology   (Belgium)

Author keywords

Brain regions; Brofaromine; MAO A; MAO B rat

Indexed keywords

4 HYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMMONIA; BROFAROMINE; HOMOVANILLIC ACID; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; MONOAMINE OXIDASE A INHIBITOR; PHENETHYLAMINE; SEROTONIN; TYRAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONOAMINERGIC NERVE; NONHUMAN; PREFRONTAL CORTEX; RAT; TELENCEPHALON;

EID: 0032190846     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00067-0     Document Type: Article

References (36)

1. ANSSEAU, M., CAILLE, P., DERKS, C., CIEREN-PUISEUX, I., WAUTHY, J., EGO, D., ROVEI, V. and JARREAU, F.X. (1992) Phase I study of repeated doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. Proceedings XVIII CINP Nice, Clin. Neuropharmacol. 15:328B.
2. BARDEN, N., REUL, J.M.H.M. and HOLSBOER, F. (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci. 18:6-11.
3. BEL, N. and ARTIGAS, F. (1995) In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:475-482.
4. BLIER, P., DE MONTIGNY, C. and AZZARO, A.J. (1986) Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: Electrophysiological studies in the rat CNS. Naunyn-Schmiedeberg's Arch. Pharmacol. 334:253-260.
5. BLIER, P. and DE MONTIGNY, C. (1994) Current advances and trends in the treatment of depression. TIPS 15:220-225.
6. BUCKHOLTZ, N.S. (1980) Neurobiology of tetrahydro-β-carbolines. Life Sci. 27:893-903.
7. BURKARD, W.P., BONETTI, E.P., DA PRADA, M., MARTIN, J.R., POLC, P., SCHAFFNER, R, SCHERSCHLICHT, R., HEFTI, F., MÜLLER, R.K.M., WYSS, P-C and HAEFELY, W. (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:391-399.
8. CELADA, P., BEL, N. and ARTIGAS, F. (1994) The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nuclei and frontal cortex of freely moving rats. J. Neural Transm., suppl 41:357-363.
9. CESURA, A. M., KETTLER, R., IMHOF, R. and DA PRADA, M. (1992) Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology 106, S15-16.
10. CHECKLEY, S. (1992) Neuroendocrine mechanisms and the precipitation of depression by life events. Brit. J. Psychiatry. 160 suppl. 15:7-17.
11. CHOUINARD, G., SAXENA, B.M., NAIR, N.P.V., KUTCHER, S.P., BAKISH, D., BRADWEJN, J., KENNEDY, S.H., SHARMA, V., REMICK, R.A., KUKHA-MOHAMAD, S.A., SNAITH, J. and D'SOUZA, J. (1992) Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative control led studies. Proceedings XVIII CINP Nice, Clin. Neuropharmacol. 15: 426A-427A.
12. DA PRADA, M., ZÜRCHER, G., WÜTHRICH and HAEFELY, W.E. (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm. suppl 26:31-56.
13. DA PRADA, M., KETTLER, R., KELLER, H. H., BURKARD, W.P., MUGGLI-MANIGLIO, D. and HAEFELY, W.E. (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:400-414.
14. DA PRADA, M., KETTLER, R., KELLER, H.H. and BURKARD (1990) Short-lasting and reversible inhibition of monoamine-oxidase-A by moclobemide. Acta Psychiatr. Scand. suppl 360:103-105.
15. DE WILDE, J.E., GEERTS, S., VAN DORPE, J., BRUHWYLER, J. and GECZY, J. (1996) A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatr. Scand. 94:404-410.
16. DINGEMANSE, J., KNEER, J., FOTTELER, B., GROEN, H., PEETERS, P.A.M. and JONKMAN, J.H.G. (1995) Switch in treatment from tricyclic antidepressants to moclobemide: A new generation monoamine oxidase inhibitor. J. Clin. Psychopharmacol. 15:41-48.
17. FITTON, A., FAULDS, D. and GOA, K.L. (1992) Moclobemide A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561-596.
18. GERARDY, J. (1994) Effect of moclobemide on rat brain monoamine oxidase A and B: Comparison with harmaline and clorgyline. Prog. Neuro-Psychopharmacol. & Biol. Psychiat 18:793-802.
19. HARE, M.L.C. (1928) Tyramine oxidase. I. A new enzyme system in liver. Biochem. J. 22:968-979.
20. JOHNSTON, J. P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem, Pharmacol. 17:1285-1297.
21. LICHTFIELD, J. T. and WILCOXON, F. (1949) A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96: 99-113.
22. LIPPER, S., MURPHY, D.L., SLATER, S. and BUCHSBAUM, M.S. (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 62:123-128.
23. MC EWEN, B.S., GOULD, E. A. and SAKAI, R.R. (1992) The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. Brit. J. Psychiatry 160 suppl 15:18-24.
24. MAÎTRE, L., DELINI-STULA, A. and WALDMEIER, P.C. (1976) Relations between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors in rats. In: Monoamine oxidase and its inhibition, G. Wolstenholme and J. Knight (Eds), pp 247-270, Ciba Foundation Symposium 39, Elsevier, Amsterdam.
25. MARINESCO, S., PONCET, L., DEBILLY, G., JOUVET, M. and CESPUGLIO, R. (1996) Effects of tianeptine, sertraline and domipramine on brain serotonin metabolism: a voltammetric approach in the rat. Brain Res. 736:82-90.
26. MONGEAU, R., BLIER, P, and de MONTIGNY C. (1997) The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res. Rev. 23: 145-195.
27. MURPHY, D.L., AULAKH, C.S. and GARRICK, N.A. (1986) How antidepressants work: cautionary conclusions based on clinical and laboratory studies of the longer-term consequences of antidepressant drug treatment. In: Antidepressants and Receptor Function, R. Porter, G. Bock and S Clark (Eds). pp 106-125, Ciba Foundation Symposium 123, Wiley, Chichester.
28. 3H]Harmaline as a specific ligand of MAO-A. I. Properties of the active site of MAO-A from rat and bovine brains. J. Neurochem. 32:1817-1827.
29. NIBUYA, M., NESTLER, E.J. and DUMAN, R.S. (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16:2365-2372.
30. RUDORFER, M. V. (1992) Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol. Bull. 28:45-57.
31. SAURA, J., BLEUEL, Z., ULRICH, J., MENDELOWTSCH, A., CHEN, K., SHIH, J.C., MALHERBE, P., DA PRADA, M. and RICHARDS, J.G. (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70:755-774.
32. SJÖQVIST, F. (1968) Toxic interactions between monoamine oxidase inhibitors (MAOI) and other drugs. In: Monoamine oxidase inhibitors: Relationship between pharmacological and clinical effects, J. Cheymol and J.R. Boissier. (Eds), pp 61-74, Proceedings of the 3rd International Pharmacological Meeting., 1966 Sao Paulo, Pergamon Press, Oxford.
33. SNYDER, S. H. and HENDLEY, E. D. (1968) A simple and sensitive fluorescence assay for monoamine oxidase and diamine oxidase. J. Pharmacol. exp. Ther., 163 : 386-392.
34. VOLTZ, H., GLEITER, C.H., STRUCK, M. and MÖLLER, H. (1995) Brofaromine: insight into the nature of drug development. CNS Drugs, 3: 1-8.
35. WALDMEIER P.C. and STÖCKLIN, K. (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur. J. Pharmacol., 169:197-204.
36. 3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide. Eur. J. Pharmacol., 180:297-304.